Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

United Therapeutics (UTHR) Stock Price & Analysis

UTHR Stock Chart & Stats

$598.72$5.18(0.87%)
At close: 4:00 PM EDT
$500$550$6003 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$593.57 - $609.99
52-Week Range
$430.02 - $609.99
Previous Close
$593.54
Volume
431.35K
Average Volume (3M)
804.65K
Market Cap
$25.68B
Enterprise Value
$22.15B
Total Cash (Recent Filing)
$2.66B
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
19.8
Beta
0.49
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
6.01
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Profitability And Cash Generation

United Therapeutics combines unusually high profitability with substantial cash generation, giving it capacity to fund clinical development, commercial expansion and organ-manufacturing initiatives internally. Strong cash conversion also improves resilience and supports flexible capital allocation over the next several quarters.

Conservative Balance Sheet

An essentially debt-free balance sheet gives United Therapeutics significant financial flexibility while reducing interest and refinancing pressure. That position can support investment in pipeline programs, facilities and strategic opportunities without requiring heavy reliance on external financing during periods of business volatility.

Broadening Clinical And Organ Pipeline

Multiple positive clinical readouts and regulatory filings create potential avenues for expanding beyond the existing PAH franchise. Ralinepag, Tyvaso in IPF, additional inhalation devices and xenotransplantation programs could diversify future growth and enlarge the company’s addressable markets.

Bears Say

Sharp Recent Revenue Decline

The sharp TTM revenue decline indicates that recent commercial performance has been uneven despite strong historical profitability. If this volatility persists, it could reduce operating leverage, make investment planning more difficult and delay the conversion of pipeline progress into sustained company-wide growth.

Tyvaso Faces Growing Competition

Competitive pressure on Tyvaso matters because the product generated approximately 58% of Q2 revenue, making the franchise central to near-term results. Greater competition could constrain volume growth, market share and commercial leverage even if patient starts and referrals continue increasing.

Revenue And Regulatory Timing Uncertainty

With 2026 guidance not reaffirmed and approval timing unresolved, the timing of revenue growth remains difficult to forecast. Delays in regulatory decisions or launch execution could postpone contributions from new indications and leave near-term results more dependent on the pressured existing franchise.

United Therapeutics News

UTHR FAQ

What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $430.02 and its highest was $609.99 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $25.68B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 3 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Aug 05, 2026. The company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.862 by $0.408.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.01.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 42,890,694 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $7.27 in its last earnings report, beating expectations of $6.862. Following the earnings report the stock price went up 0.064%.
Which hedge fund is a major shareholder of United Therapeutics?
Hedge funds hold United Therapeutics shares: the largest hedge-fund position in United Therapeutics is 71,888,307 shares, and hedge funds decreased their holdings by 150.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology